Latest Conference Coverage


AHS 2019: What You Need to Know Ahead of the American Headache Society Annual Meeting

AHS 2019: What You Need to Know Ahead of the American Headache Society Annual Meeting

July 8th 2019

Stephen D. Silberstein, MD, past AHS president and Editor in Chief of NeurologyLive, provides a preview of premier sessions that will take place at the upcoming annual meeting.


Sharon Chiang, MD, PhD: Recording Seizures With Detection Technology

Sharon Chiang, MD, PhD: Recording Seizures With Detection Technology

July 8th 2019

The neurology resident at the University of California San Francisco discussed how new wearable technology and electronic diaries have helped improve the understanding of seizure rhythmicity, and ultimately, epilepsy care.


Improving Epilepsy Care By Systematically Measuring Seizure Rhythmicity

Improving Epilepsy Care By Systematically Measuring Seizure Rhythmicity

July 5th 2019

In order to improve patient care in epilepsy, physicians need a more consistent and cohesive method of recording patient seizure activity. As wearables get more sensitive and specific, using them in tandem with electronic seizure diaries may help address the challenge.


Marisa McGinley, DO: Advantages of Outpatient Telemedicine in Neurology Subspecialties

Marisa McGinley, DO: Advantages of Outpatient Telemedicine in Neurology Subspecialties

July 5th 2019

The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.


Making MS Therapy Decisions in an Ever-Evolving Treatment Landscape

Making MS Therapy Decisions in an Ever-Evolving Treatment Landscape

July 4th 2019

The MS neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the impact that propensity score has had on real-world data analysis, the use of additional outcome measures in trials, and the increasing understanding of progressive disease.


Brian J. Murray, MD: Establishing Normal Values in Polysomnography

Brian J. Murray, MD: Establishing Normal Values in Polysomnography

July 3rd 2019

The head of neurology at the Sunnybrook Health Sciences Centre of the University of Toronto spoke about the limited available normative sleep data, and shared insight into the findings of the meta-analysis he and colleagues conducted of more than 150 studies.


Sharon Chiang, MD, PhD: The Usefulness of Seizure Diaries in Epilepsy

Sharon Chiang, MD, PhD: The Usefulness of Seizure Diaries in Epilepsy

July 2nd 2019

The neurology resident at the University of California San Francisco spoke about the role that seizure diaries can play in a patient’s peace of mind, as well as in the understanding of that patient’s response to a given treatment.


Michael J. Thorpy, MBChB: The Subtle Manifestations of Cataplexy

Michael J. Thorpy, MBChB: The Subtle Manifestations of Cataplexy

June 28th 2019

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center spoke about one of the major symptoms of narcolepsy and how to identify it during diagnosis.


Site Logo

Preventive Treatment in Tuberous Sclerosis Complex Lowers Risk for Refractory Epilepsy

June 27th 2019

Patients whose EEG changes were monitored prior to onset of clinical seizures and who were given preventive therapy demonstrated a lower risk of epilepsy overall, especially drug-refractory.


Epileptogenic Zone, Epilepsy Duration, and Interictal Discharges Predict Postoperative Seizure Outcomes

Epileptogenic Zone, Epilepsy Duration, and Interictal Discharges Predict Postoperative Seizure Outcomes

June 26th 2019

A trio of predictors may help inform which patients may be candidates for resective surgery, as well as improve the postsurgical consideration for re-operation on those who experience disabling seizure recurrence.


Lara Jehi, MD: Epilepsy Treatment Algorithms as Personalized Medicine

Lara Jehi, MD: Epilepsy Treatment Algorithms as Personalized Medicine

June 26th 2019

The professor of neurology at Cleveland Clinic’s epilepsy center discussed how algorithms can better influence the personalization of medicine, not just in the field of epilepsy, but in medicine as a whole.


In Intractable Epilepsy, Rufinamide is Well-Tolerated and Effective

In Intractable Epilepsy, Rufinamide is Well-Tolerated and Effective

June 26th 2019

Data suggest that rufinamide is capable of aiding in the control and reduction of seizures, as well as the possible achievement of seizure-freedom in pediatric patients with genetic/metabolic, hypoxic-ischemic, structural, and other intractable epilepsies.


Sanjeev V. Thomas, MD, DM: Managing Epilepsy During Pregnancy

Sanjeev V. Thomas, MD, DM: Managing Epilepsy During Pregnancy

June 26th 2019

The chief of neurology at Sree Chitra Tirunal Institute for Medical Sciences and Technology spoke about how to reassure patients with epilepsy who are planning for pregnancy and how to make treatment decisions with pregnant patients.


Intermittent Adherence to Ketogenic Diet As Effective as Daily Adherence in Drug-Resistant Epilepsy

Intermittent Adherence to Ketogenic Diet As Effective as Daily Adherence in Drug-Resistant Epilepsy

June 25th 2019

Investigators compared an intermittent low glycemic index therapy diet, a version of the ketogenic diet, to a daily version in pediatric patients with drug-refractory epilepsy.


Sleep Disorders Have Significant Impact on Patients With Epilepsy

Sleep Disorders Have Significant Impact on Patients With Epilepsy

June 25th 2019

Several poster presentations at IEC 2019 suggest that the incidence of comorbid sleep disorders in people with epilepsy is higher than estimated and have a detrimental impact on quality of life and social adjustment.


Cerliponase Alfa Shows Long-Term Success in CLN2 Disease

Cerliponase Alfa Shows Long-Term Success in CLN2 Disease

June 25th 2019

Patients with CLN2 disease have shown a maintained treatment benefit, high rate of response, and lowering rates of seizure occurrence over 3 years in an ongoing extension trial.


Hannah Cock, MD, MBBS: Challenges in Treating Status Epilepticus

Hannah Cock, MD, MBBS: Challenges in Treating Status Epilepticus

June 25th 2019

The professor of epilepsy and medical education at St. George’s University Hospital London spoke about the number of challenges plaguing epileptologists when treating patients who present with possible status epilepticus in the hospital.


Anup Patel, MD: The Role of Technology in Epilepsy

Anup Patel, MD: The Role of Technology in Epilepsy

June 25th 2019

The section chief of neurology at Nationwide Children's Hospital spoke about the role of wearable technology in pediatric epilepsy, an area that has the potential to make a major impact on treatment.


Naboso Technology in Multiple Sclerosis

Naboso Technology in Multiple Sclerosis

June 24th 2019

The podiatrist and chief executive officer of Naboso Technology spoke about the potential of textured insoles to help patients with multiple sclerosis improve gait, posture, and balance.


No Drug-Drug Interaction Between Epidiolex and Stiripentol in Epilepsy

No Drug-Drug Interaction Between Epidiolex and Stiripentol in Epilepsy

June 24th 2019

The GW Pharmaceuticals cannabidiol formulation, marketed as Epidiolex, did not show any evidence of clinically relevant drug-drug interactions when co-administered in patients with epilepsy.


Improvements in Psychosocial Factors, Quality of Life Key to Epilepsy Surgery Satisfaction

Improvements in Psychosocial Factors, Quality of Life Key to Epilepsy Surgery Satisfaction

June 24th 2019

While 65% of patients indicated that they no longer have epilepsy, only a quarter of the study population were actually completely free of seizures postoperatively.


Lara Jehi, MD: Using Algorithms in Epilepsy Care

Lara Jehi, MD: Using Algorithms in Epilepsy Care

June 24th 2019

The professor of neurology at Cleveland Clinic’s epilepsy center spoke about the limitations of individual physicians in making clinical decisions, and how utilizing algorithm data can help improve epilepsy interventions.


Perampanel Does Not Worsen Myoclonic or Absence Seizures in Patients With Epilepsy

Perampanel Does Not Worsen Myoclonic or Absence Seizures in Patients With Epilepsy

June 24th 2019

Overall, myoclonic and absence seizures worsened in 1.2% and 15.9% more patients in the placebo group, respectively, than those given perampanel. The reductions in seizure frequency and the increases in seizure-free days were also greater with the noncompetitive AMPA receptor antagonist.


Neurorehabilitation Outcomes Similar for Patients With and Without Poststroke Seizures

Neurorehabilitation Outcomes Similar for Patients With and Without Poststroke Seizures

June 24th 2019

An assessment of 230 poststroke patients determined that neurorehabilitation outcomes and length of stay did not differ between those with poststroke epileptic seizures and those without.


Intranasal Midazolam Rapidly Effective, Safe Alternative to Intravenous Therapy in Status Epilepticus

Intranasal Midazolam Rapidly Effective, Safe Alternative to Intravenous Therapy in Status Epilepticus

June 23rd 2019

Over 57% of patients who received intranasal midazolam were responders, with status epilepticus ceasing within an average of 5:05 minutes.


Perampanel Monotherapy Promotes Seizure Freedom in Previously Untreated Partial Onset Epilepsy

Perampanel Monotherapy Promotes Seizure Freedom in Previously Untreated Partial Onset Epilepsy

June 23rd 2019

Preliminary results from the 4 mg maintenance period of the FREEDOM study, the first in which perampanel has been examined as monotherapy, were presented at the 2019 International Epilepsy Congress in Bangkok.


Lacosamide Shows Seizure Freedom Success in Epilepsy

Lacosamide Shows Seizure Freedom Success in Epilepsy

June 22nd 2019

In a retrospective study, 51.7% of patients achieved seizure freedom while receiving lacosamide, with seizure freedom rates going as high 88.9% for those who were administered the drug as monotherapy.


Levetiracetam Inferior to Valproate in Generalized, Unclassified Epilepsy

Levetiracetam Inferior to Valproate in Generalized, Unclassified Epilepsy

June 21st 2019

Findings from SANAD II have suggested that levetiracetam is inferior to valproate in time to 12-month and 24-month remission in patients with generalized or unclassified epilepsy.


Amy B. Sullivan, PsyD: Screening MS Patients for Comorbidities

Amy B. Sullivan, PsyD: Screening MS Patients for Comorbidities

June 21st 2019

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of screening patients with MS for other conditions for which they are prevalently comorbid, such as depression or sleep disorders.


Peter Goadbsy, MD, PhD, DSc: Atogepant Has Potential as Migraine Prophylactic

Peter Goadbsy, MD, PhD, DSc: Atogepant Has Potential as Migraine Prophylactic

June 20th 2019

The professor of neurology at both the University of California San Francisco and King’s College, London, spoke about the results from a phase 2b/3 study evaluating atogepant for prevention of migraine.

© 2024 MJH Life Sciences

All rights reserved.